INT280027

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.15
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 1.13
Pain Relevance 0.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Dpp4) extracellular region (Dpp4) cell adhesion (Dpp4)
Golgi apparatus (Dpp4) endoplasmic reticulum (Dpp4) plasma membrane (Dpp4)
Dpp4 (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 66 93.00 High High
abdominal pain 2 34.60 Quite Low
cytokine 4 5.00 Very Low Very Low Very Low
ischemia 4 5.00 Very Low Very Low Very Low
tolerance 4 5.00 Very Low Very Low Very Low
withdrawal 2 5.00 Very Low Very Low Very Low
Inflammatory marker 2 5.00 Very Low Very Low Very Low
Neuropeptide 2 5.00 Very Low Very Low Very Low
Paracetamol 2 5.00 Very Low Very Low Very Low
rheumatoid arthritis 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypoglycemia 60 97.72 Very High Very High Very High
Diabetes Mellitus 206 96.16 Very High Very High Very High
Vomiting 20 67.68 Quite High
Weight Loss 28 51.60 Quite High
Abdominal Pain 2 34.60 Quite Low
Appetite Loss 2 33.96 Quite Low
Targeted Disruption 6 33.84 Quite Low
Diarrhoea 4 33.56 Quite Low
Hyperinsulinism 4 28.40 Quite Low
Constipation 2 27.52 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Albiglutide, a DPP-4-resistant GLP-1 analog which is administered weekly, reduced fasting and postprandial glucose levels without causing hypoglycemia in healthy subjects87 and T2DM patients.88 A dose of 32 mg reduced 24-hour mean weighted glucose by 35 mg/dL (?
Negative_regulation (reduced) of Localization (analog) of DPP-4-resistant associated with hypoglycemia and diabetes mellitus
1) Confidence 0.15 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731024 Disease Relevance 0.57 Pain Relevance 0.16
Albiglutide, a DPP-4-resistant GLP-1 analog which is administered weekly, reduced fasting and postprandial glucose levels without causing hypoglycemia in healthy subjects87 and T2DM patients.88 A dose of 32 mg reduced 24-hour mean weighted glucose by 35 mg/dL (?
Negative_regulation (administered) of Localization (analog) of DPP-4-resistant associated with hypoglycemia and diabetes mellitus
2) Confidence 0.15 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731024 Disease Relevance 0.56 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox